---
category: news
title: "Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second Quarter"
excerpt: "Kiromic achieves key milestone for this first-in-human Phase 1 clinical trial with a target derived by Kiromicâ€™s AI platform. HOUSTON-- ( BUSINESS WIRE )--Kiromic Biopharma, Inc. (Nasdaq: KRBP), an immuno-oncology target discovery and gene-editing company with a proprietary artificial intelligence neural network platform (Diamond AI) that is used to develop novel oncology therapeutics,"
publishedDateTime: 2021-05-24T15:55:00Z
originalUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
webUrl: "https://www.businesswire.com/news/home/20210524005256/en/Kiromic-Announces-FDA-IND-Submission-First-In-Human-AI-derived-Off-The-Shelf-IsoMesothelin-Gamma-Delta-CAR-T-cell-Therapy-30-Days-Before-the-End-of-the-Second-Quarter"
type: article

provider:
  name: Business Wire
  domain: businesswire.com

topics:
  - AI in Healthcare
  - AI

secured: "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;KrSBdyw2E50+Z6ZOhxHm+g=="
---

